Enlivex Therapeutics Ltd. (ENLV)
Stock Price:
$5.46 USD
-0.12 (-2.15%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
After-hours: $5.40 -0.06 (-1.10%) Jul 31, 5:18 PM
Key Info
| Market Cap |
73.32M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.38M |
| Shares Out |
13.43M |
| EPS (ttm) |
-0.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$5.46 |
| Previous Close |
$5.58 |
| Change ($) |
-0.12 |
| Change (%) |
-2.15% |
| Day's Open |
5.51 |
| Day's Range |
5.39 - 5.62 |
| Day's Volume |
99,702 |
| 52-Week Range |
3.59 - 44.90 |
More Stats
| Market Cap |
73.32M |
| Enterprise Value |
59.81M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.43M |
| Float |
7.31M |
| EPS (basic) |
-1.11 |
| EPS (diluted) |
-0.73 |
| FCF / Share |
-0.84 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10,822 |
| Short Ratio |
0.13 |
| Short % of Float |
0.23% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.38 |
| Revenue |
n/a |
| Operating Income |
-8.62M |
| Net Income |
-9.38M |
| Free Cash Flow |
-7.23M |
| Net Cash |
13.51M |
| Net Cash / Share |
1.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-17.98% |
| ROE |
-33.01% |
| ROIC |
-266.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
22.0
Current: $5.46
High
22.0
Target: 22.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -8.62 | -5.30 | -2.17 | -2.82 | -15.48 | -7.08 | -1.15 | -0.23 |
| Net Income | -9.38 | -4.24 | -2.50 | -2.88 | -15.37 | -7.02 | -1.15 | -0.23 |
| Shares Outstanding | 8.65 | 3.51 | 3.43 | 3.36 | 0.36 | 0.31 | 0.21 | 0.19 |
| Earnings Per Share | -1.11 | -1.40 | -0.94 | -1.03 | -43.20 | -22.80 | -5.60 | -1.20 |
| Operating Cash Flow | -7.04 | -3.16 | -2.30 | -2.19 | -13.25 | -4.41 | -0.87 | -0.15 |
| Capital Expenditures | -0.19 | -0.46 | -0.13 | -0.18 | -0.05 | -0.06 | - | - |
| Free Cash Flow | -7.23 | -3.62 | -2.43 | -2.37 | -13.30 | -4.47 | -0.87 | -0.15 |
| Cash & Equivalents | 13.51 | 9.78 | 9.01 | 9.88 | 19.33 | 32.61 | 0.27 | 0.00 |
| Net Cash / Debt | 13.51 | 9.78 | 9.01 | 9.88 | 19.33 | 32.61 | 0.27 | 0.00 |
| Assets | 17.56 | 11.03 | 9.54 | 10.63 | 20.52 | 32.95 | 0.31 | - |
| Liabilities | 6.28 | 1.33 | 1.05 | 1.93 | 2.58 | 2.28 | 0.13 | - |
| Book Value | 11.28 | 9.71 | 8.49 | 8.70 | 17.93 | 30.67 | 0.18 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Enlivex Therapeutics Ltd. |
| Country |
Israel |
| Employees |
36 |
| CEO |
Oren Hershkovitz |
Stock Information
| Ticker Symbol |
ENLV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ENLV |
| IPO Date |
December 12, 1995 |
Description
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.